Information in the news releases is current on the date of the announcement, but is subject to change without prior notice. |
| 2007 Release |
 |
| December 27, 2007 |
|
U.S. District Court Decision about Eisai's Legal Action over Aricept ODT® ANDA Filing
|
|
| December 25, 2007 |
|
Eisai Introduces New Aricept® Dose Formulations for Treatment of Severe Alzheimer's Disease in Japan
|
|
| December 18, 2007 |
|
Eisai Enters into In-licensing Agreement with Minophagen Pharmaceutical for Liver Disease/Allergic Disease Agents Stronger Neo-Minophagen® C and Glycyron® Tablets for Allergic Disease
|
|
| December 10, 2007 |
|
Eisai to Acquire MGI PHARMA, INC.
|
|
| December 6, 2007 |
|
Eisai Celebrates Ground-Breaking Ceremony For New Manufacturing and Research Base in India
|
|
| December 4, 2007 |
|
Eisai and BioArctic Neuroscience Enter Exclusive Licensing Agreement with Novel Antibody Treatment for Alzheimer's Disease
|
|
| November 29, 2007 |
|
Eisai Submits NDA Application of KES524 for Obesity Management in Japan
|
|
| October 30, 2007 |
|
Eisai Announces Change in Regulatory Submission Strategy of E2007 for Parkinson's Disease
|
|
| September 28, 2007 |
|
Eisai Announces Establishment of New Pharmaceutical Marketing Subsidiary in Belgium
|
|
| September 28, 2007 |
|
Kissei and Eisai sign a license agreement to develop and commercialize Glufast®, a rapid-acting insulin secretagogue in China
|
|
| September 25, 2007 |
|
Abbott and Eisai submit application for adalimumab, the only fully human monoclonal anti-TNF antibody, to treat psoriasis
|
|
| September 5, 2007 |
|
Eisai Inc. Enters Exclusive Agreement with Salix Pharmaceuticals, Ltd. to Co-promote “COLAZAL®” for the Treatment of Ulcerative Colitis in the U.S. Market
|
|
| August 24, 2007 |
|
Approval of an additional dosage and administration for secondary eradication of Helicobacter pylori for proton pump inhibitors in Japan
|
|
| August 23, 2007 |
|
Aricept® Receives Approval for Additional Efficacy and Dosage For Treatment of Severe Alzheimer's Disease in Japan
|
|
| August 23, 2007 |
|
Sanko Junyaku and Eisai to Co-promote “Picolumi® ucOC”, Diagnostic Agent Introduced by Sanko Junyaku
New Diagnostic Agent Helps Physicians Make Prescribing Choice for Vitamin K2 Medication Therapy for Osteoporosis Patients
|
|
| August 11, 2007 |
|
UK High Court Ordered NICE To Amend A Guidance for Alzheimer's Disease
|
|
| August 10, 2007 |
|
UK High Court Ruled NICE Guidance for Alzheimer's Disease Discriminatory
|
|
| July 31, 2007 |
|
Continuation of Policy for Protection of the Company's Corporate Value and Common Interests of Shareholders
|
|
| July 27, 2007 |
|
Eisai Co-promotes “PyloriTek® Test Kit”, H. Pylori Infection Diagnostic Kit Launched by Sanko Junyaku
|
|
| July 27, 2007 |
|
Eisai Enters into In-licensing Agreement with Sepracor for Eszopiclone Insomnia Treatment
|
|
| July 17, 2007 |
|
New Individually-Wrapped Tablets Introduced to Selbelle®:
Stomach Medication that Protects Gastric Mucosa from Stomach Acid Now Available in Easy-to-Carry Package
|
|
| July 11, 2007 |
|
Eisai Launches “Nitorol® Injection 5 mg Syringe” and “Nitorol® Continuous Intravenous Infusion 25 mg Syringe”, First Nitric Acid Syringe Formulations Approved in Japan
|
|
| July 9, 2007 |
|
Notice on Details of Stock Options (New Share Acquisition Rights) to be Allocated
|
|
| June 26, 2007 |
|
Tambocor® (Antiarrthymic Treatment) Received Approval for Paroxysmal Atrial Fibrillation/Flutter
|
|
| June 22, 2007 |
|
Notice on Allocation of Stock Options (Stock Acquisition Rights)
|
|
| June 16, 2007 |
|
Inovelon® launched in Germany
|
|
| June 15, 2007 |
|
A ONCE-WEEKLY ANTIOSTEOPOROTIC AGENT “ACTONEL® 17.5 mg TABLETS” IS LAUNCHED.
|
|
| June 12, 2007 |
|
Kissei and Eisai sign a license agreement to develop and commercialize Glufast®, a rapid-acting insulin secretagogue in 10 ASEAN countries
|
|
| May 15, 2007 |
|
Eisai Signs Exclusive Agreement to Commercialize NeuroBloc® for Europe
|
|
| May 15, 2007 |
|
Eisai Submits Application for Gastroprokinetic Agent Gasmotin® in Thailand
|
|
| May 15, 2007 |
|
Notice on New Stock Issuance in the Form of Stock Options
|
|
| May 15, 2007 |
|
Basic Principle and Policies concerning Reduction of Minimum Trading Lots for Shares
|
|
| May 12, 2007 |
|
EISAI OBTAINS FAVORABLE RULING IN ACIPHEX® PATENT INFRINGEMENT LAWSUIT AGAINST TEVA PHARMACEUTICALS AND DR. REDDY'S LABORATORIES
|
|
| May 7, 2007 |
|
Eisai Introduces “Chocola BB® Light 2” Vitamin B2 Drink
A New Drink with Enhanced Formula and Reduced Calories
|
|
| May 7, 2007 |
|
FDA Approves FRAGMIN®, an Injectable Anti-Clotting Agent, for Extended Treatment to Reduce the Recurrence of Blood Clots in Patients with Cancer
|
|
| April 26, 2007 |
|
Eisai Announces Complete Subsidiarization of Sanko Junyaku
|
|
| April 18, 2007 |
|
A ONCE-WEEKLY FORMULATION OF RISEDRONATE SODIUM HYDRATE, AN ANTIOSTEOPOROTIC AGENT, WAS APPROVED.
|
|
| April 17, 2007 |
|
Eisai Announces Completion of Acquisition of Morphotek
|
|
| April 13, 2007 |
|
Eisai Withdraw Application for Additional Indication of Aricept® for Treatment of Severe Alzheimer's Disease in Europe
|
|
| March 26, 2007 |
|
Asahi Kasei Pharma Corporation and Eisai Co., Ltd.
Signed License Agreement for Vasodilator Eril® in Korea
|
|
| March 22, 2007 |
|
EISAI TO ACQUIRE MORPHOTEK
Eisai's Dramatic Leap towards Biologic Therapeutics Evidenced by the Acquisition
|
|
| March 5, 2007 |
|
Eisai Establishes New Manufacturing Subsidiary in United Kingdom
|
|
| March 1, 2007 |
|
Eisai and Abbott Announce Amendment to Agreement for the Co-promotion of Rheumatoid Arthritis Drug HUMIRA® in Taiwan and Korea
|
|
| February 2, 2007 |
|
Notice Regarding Revision of Year End Dividend Forecast For Fiscal Year Period (95th Company Fiscal Period) Ending March 2007
|
|
| January 30, 2007 |
|
Proton Pump Inhibitor Pariet® Tablets 10mg Receives Approval in Japan for Helicobacter Pylori Eradication
|
|
| January 22, 2007 |
|
Inovelon® recieves Marketing Authorization Approval from European Commission
|
|
| | | |
